HealthcareBringing Checks and Balances to Peptide Medicine

Synthetic peptides have become an extremely popular wellness trend, promising users results that range from anti-aging to weight control to muscle growth. But experts are concerned that the lack of regulation in peptide medicine is resulting in risks users may not know they are assuming. Additionally, some feel that the trust users place in the companies and clinics providing peptides may be misplaced.

“Peptide medicine became a major commercial category before it became a governed one,” says Karthik Achari, Clinician and Founder of PepMD. “Patients are being prescribed compounded peptides at clinics across the country, often without standardized credentialing of the clinician, without recognized pharmacy quality controls, and without research that is approved by an internal review board (IRB) or that generates real-world outcomes data. The result is a market where patients can’t tell a credentialed clinician from a marketing claim.”

Achari is a clinician with a background in pharmaceutical infrastructure, where he saw firsthand the need for greater consistency and accountability in the GLP-1 and peptide industries. He founded PepMD in 2026 after seeing peptide medicine growing at a rapid pace without a similar advance in infrastructure to support it. PepMD addresses the problem by providing credentials to clinicians, recognizing pharmacies, and authorizing research sites under a single, unified standard.

“The downstream consequences of the current state of the peptide industry are predictable,” Achari says. “Patients can’t evaluate the provider. Providers can’t evaluate the pharmacy. And every gatekeeper above them, from payment processors to malpractice carriers, treats the entire category as a single risk class. That isn’t sustainable for the patients, the providers, or the science.”

What many users don’t understand about peptide therapy

Natural peptides are short chains of amino acids, which are the same elements used to build proteins. They are used by the body as signaling molecules, sending messages that prompt it to perform a range of important functions, from muscle growth to cellular repair to hormone production.

Synthetic peptides were developed to mimic the performance of natural peptides while providing greater stability and improved efficacy. Lab-produced insulin, for example, is a synthetic peptide developed to help better regulate blood sugar levels.

Some synthetic peptides have received FDA approval, such as the peptide-based semaglutide Ozempic, which is used to treat Type 2 diabetes, and the growth hormone Sermorelin. Many of the peptides being used in today’s trending wellness treatments, however, are not FDA-approved. In fact, the system that produces today’s synthetic peptides primarily operates outside the standard system of medical checks and balances.

“I’m a clinician trained in a system that takes credentialing for granted,” Achari says. “Every specialty has boards. Every hospital has privileging. And every reasonable lab has accreditation. In the realm of peptide medicine, none of that exists.”

One of the top problems with the lack of governance in the peptide industry is a lack of reliable research. While many companies selling peptide therapeutics claim their products have been researched, medical experts say they are most likely not using the standards that are common in the medical industry.

“Almost no one calling themselves a peptide researcher actually is one,” Achari says. “Most are taking research compounds, sourcing peptides from vendors that label the product ‘not for human consumption,’ administering them to themselves or paying clients to take an injection, and calling that activity research. There’s no IRB, no protocol, no principal investigator, and no adverse events being reported. That isn’t research. It’s self-experimentation with a vocabulary borrowed from research.”

While not all peptide products are produced under the conditions Achari describes, many are. And because there are no standards for the industry, patients can’t tell the difference between the two. Additionally, the lack of credentialing for clinicians means those taking a more serious approach to peptide use have no way to distinguish themselves from those who aren’t.

How credentialing can improve the way peptides are made and administered

A credentialing organization, such as Achari’s PepMD, creates a trust infrastructure for peptide medicine that would ensure that clinicians, pharmacies, and research facilities comply with the regulatory standards imposed on them. And where regulatory standards are lacking, the organization would ensure that practices align with modern, tested, and proven medical standards.

Clinicians would benefit from credentialing by having a defensible standard that could show they have been evaluated against a published competency framework. In a category increasingly scrutinized by the public, the press, and state pharmacy boards, that credential is the difference between defensible practice and exposure.

“For pharmacies, the benefit of credentialing is recognition tied to compounding quality rather than commercial volume,” Achari says. “It would allow pharmacies to show they were meeting defined requirements for sourcing, sterility, beyond-use dating, and quality documentation. Patients seeking peptides from such pharmacies would have a way to identify quality that’s verified rather than simply assumed.”

Research facilities receiving credentialing would benefit from participating in IRB-approved research with a recognized framework. It would allow them to show that their outcome data has come from a defensible source.

“The peptides making wellness headlines today aren’t all dangerous, but the system that delivers them to patients often is,” Achari warns. “Without a recognized standard that establishes which clinicians are qualified to prescribe peptides, which pharmacies provide peptides that meet quality requirements, and which research frameworks are defensible, peptide users are navigating the field and its many risks on their own.”